Compare Stocks

Intellia Therapeutics (NTLA) announced highlights from its seven presentations at the American College of Allergy, Asthma & Immunology 2026 Annual Scientific Meeting in Phoenix, Arizona. Intellia will host an investor

JPMorgan raised the firm’s price target on Intellia Therapeutics (NTLA) to $9 from $8 and keeps an Underweight rating on the shares. Published first on TheFly – the ultimate source

BofA lowered the firm’s price target on Intellia Therapeutics (NTLA) to $16 from $17 and keeps a Neutral rating on the shares. Published first on TheFly – the ultimate source

Reports Q3 revenue $7.16M, consensus $9.77M. “This is a defining period for Intellia as we advance our late-stage pipeline and prepare for a transformative year ahead,” said John Leonard, Intellia

Intellia Therapeutics (NTLA) announced the appointment of Jing Marantz as executive VP and chief medical officer, effective October 26. Marantz will lead the company’s translational, development, regulatory and medical affairs

On Monday, Cathie Wood’s ARK Invest sold 4,520 shares of Meta Platforms ($META) through its ARK Innovation ETF ($ARKK). Based on Meta’s closing price of $742.96, the sale was worth

What has Wall Street been buzzing about this week? Here are the top 5 Buy calls and the top 5 Sell calls made by Wall Street’s best analysts during the

The major averages were higher for a second day in a row amid a Treasury yield retreat and a nearly 2% decline in oil prices. The market’s broader gains were

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by

Barclays initiated coverage of Intellia Therapeutics (NTLA) with an Underweight rating and $8 price target The firm sees headwinds for the company’s late-stage assets in hereditary angioedema and transthyretin amyloidosis.